{
    "clinical_study": {
        "@rank": "4748", 
        "arm_group": {
            "arm_group_label": "Bendamustine+Pomalidomide+Dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "Study treatment will be as follows, in 28 day cycles:\nPomalidomide: once daily PO dosing on days 1-21, every 28 days\nBendamustine: once IV dosing on day 1, every 28 days\nDexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22\nAfter completing 6 cycles of treatment, dexamethasone will be decreased to 20mg. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide 4 mg on day 1-21, every 28 days and dexamethasone 20 mg on days 1, 8, 15, and 22 every 28 days until time of progression. Study treatment will be administered starting at Cohort 1 for up to four sequential cohorts, with 3-6 patients in each cohort. A standard 3+ 3 dose escalation schedule will be used. Once the MTD is reached, any additional patients will be enrolled at the MTD level, up to a total of 30 patients."
        }, 
        "brief_summary": {
            "textblock": "This study is designed as a phase I-II, open label, dose finding study.\n\n      Study treatment will be as follows, in 28 day cycles:\n\n        -  Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days\n\n        -  Bendamustine: once intravenously (IV) dosing on day 1, every 28 days\n\n        -  Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22.\n\n      After completing 6 cycles of treatment, dexamethasone will be decreased to 20mg. After\n      completing 12 cycles of treatment, patients will proceed to the maintenance phase of the\n      study. Patients will receive Pomalidomide 4 milligrams (mg) on day 1-21, every 28 days and\n      dexamethasone 20 mg on days 1, 8, 15, and 22 every 28 days until time of progression."
        }, 
        "brief_title": "Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma", 
        "completion_date": {
            "#text": "January 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Cytopathologically or histologically confirmed diagnosis of multiple myeloma\n\n          2. Relapsed or refractory to the most recently received therapy. Refractory disease is\n             defined as < 25% response or progression during therapy or within 60 days after\n             completion.\n\n          3. All patients must have received prior lenalidomide therapy and been determined to be\n             refractory. Refractory will be defined as a history of progression on a regimen\n             containing full or maximally tolerated dose of lenalidomide administered for a\n             minimum of at least two completed cycles of therapy.\n\n          4. Measurable disease as specified in the protocol\n\n          5. Prior to enrollment, sites must provide evidence of myeloma progression/relapse and\n             evidence of being refractory to lenalidomide, with start and stop dates of\n             lenalidomide therapy and the most recent treatment regimen, as well as best tumor\n             response to all prior treatment regimens.\n\n          6. Males and females 18 years of age or older\n\n          7. Life expectancy of more than 3 months\n\n          8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n\n          9. Adequate hepatic function, with total bilirubin < 2 times the upper limit of normal\n             (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3\n             times ULN\n\n         10. Serum creatinine <3 mg/dL\n\n         11. Laboratory tests meet the levels specified in the protocol\n\n         12. Patients must agree to take enteric coated aspirin 81 mg orally daily, or if history\n             of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or\n             be treated with full dose, low molecular weight heparin, as if to treat deep venous\n             thrombosis (DVT)/pulmonary embolism (PE)\n\n         13. Written informed consent in accordance with federal, local, and institutional\n             guidelines\n\n         14. Females of Child Bearing Potential (FCBP) must meet requirements for pregnancy\n             testing and use approved methods of contraception.\n\n         15. Male patients must use approved methods of contraception.\n\n         16. All study participants must be registered into the mandatory POMALYST REMS\u2122 program,\n             and be willing and able to comply with the requirements of the POMALYST REMS\u2122\n             program.\n\n        Exclusion Criteria:\n\n          1. Patients with known sensitivity to any immunomodulatory drugs (IMiDs)\n\n          2. Use of any other experimental drugs or therapy within 21 days of study-related drug\n             therapy.\n\n          3. Exposure to any prior chemotherapy or steroids use within 14 days of screening\n             assessment. (steroids use allowed if necessary to treat spinal cord compression).\n\n          4. Any prior use of bendamustine.\n\n          5. Any prior use of pomalidomide.\n\n          6. Radiation therapy within 14 days of screening.\n\n          7. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and\n             skin changes).\n\n          8. Plasma cell leukemia.\n\n          9. Waldenstr\u00f6m's macroglobulinemia.\n\n         10. Major surgery within 21 days prior to first dose.\n\n         11. Pregnant or lactating females.\n\n         12. Congestive heart failure (New York Heart Association class III to IV), symptomatic\n             ischemia, conduction abnormalities uncontrolled by conventional intervention or\n             myocardial infarction in the previous six months.\n\n         13. Uncontrolled hypertension\n\n         14. Acute active infection requiring systemic antibiotics, antivirals, or antifungals\n             within 14 days prior to first dose.\n\n         15. Patients receiving active treatment or intervention for any other malignancy or\n             patients who, at the investigator's discretion, may require active treatment or\n             intervention for any other malignancy within 8 months of starting study treatment.\n\n         16. Serious psychiatric or medical conditions that could interfere with treatment\n\n         17. Significant neuropathy (Grade 3, Grade 4) at the time of the first dose and/or within\n             14 days before enrollment\n\n         18. Contraindication to any of the required concomitant drugs, including, including\n             proton pump inhibitor (e.g. lansoprazole), enteric coated aspirin or if a history of\n             prior thrombotic disease, warfarin or low molecular weight heparin\n\n         19. Patients with primary systemic amyloidosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754402", 
            "org_study_id": "Pro00040206", 
            "secondary_id": "PO-MM-PI-0045"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bendamustine+Pomalidomide+Dexamethasone", 
                "description": "Bendamustine will be Aadministered intravenously over one hour.", 
                "intervention_name": "Bendamustine", 
                "intervention_type": "Drug", 
                "other_name": "Treanda"
            }, 
            {
                "arm_group_label": "Bendamustine+Pomalidomide+Dexamethasone", 
                "intervention_name": "Pomalidomide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CC-4047", 
                    "Pomalyst"
                ]
            }, 
            {
                "arm_group_label": "Bendamustine+Pomalidomide+Dexamethasone", 
                "description": "For subjects \u2265 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Dexamethasone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bendamustine", 
                "Nitrogen Mustard Compounds", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Multiple Myeloma", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Cristina Gasparetto, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I-II Study of the Combination of Bendamustine and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "gaspa001@mc.duke.edu", 
            "last_name": "Cristina Gasparetto, MD", 
            "phone": "919-668-1017"
        }, 
        "overall_contact_backup": {
            "email": "kimberly.bartlett@duke.edu", 
            "last_name": "Kimberly Oates, RN", 
            "phone": "919-668-6524"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Cristina Gasparetto, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "In the phase I dose escalation portion, patients will be sequentially enrolled in 4 cohorts at dose levels defined in section 3.1 in a standard 3+3 design until the maximum tolerated dose (MTD) is reached. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD). Up to 24 patients will be enrolled in phase I portion.", 
                "measure": "Maximum tolerated dose level", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks after starting the study drug"
            }, 
            {
                "description": "Response rate (complete response + partial response) -  number of patients achieving a complete response or partial response", 
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "best response with up to a minimum of 2 cycles of therapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754402"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University Medical Center", 
            "investigator_full_name": "Cristina Gasparetto", 
            "investigator_title": "Sponsor Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "the number of patients achieving stable disease (SD), minimal response/minor response (MR), partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR)", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "Time to progression - defined as time elapsed in patients between achievement of response and disease progression", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "Time to next Therapy - defined as the time elapsed for patients from initiation of study therapy until initiation of next therapy", 
                "measure": "Time to next therapy", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "The time elapsed for patients between initiation of study therapy and either disease progression or death", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Cristina Gasparetto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}